All In Biotech

Drug Trial Radar · NCT07188766

Efficacy of Liberal Versus Restricted IV Fluid Approach in the Management of Sickle Cell Vaso-Occlusive Crisis

Fluid Management in Sickle Cell Disease Vaso-occlusive Crisis: Restrictive Versus Liberal Strategies: A Randomized Controlled Trial (FLASC Trial)

Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 394 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

394

Planned (sponsor's estimate)

Start

Oct 5, 2025

Primary completion

Aug 2028

Study completion Oct 2028

Sponsor

Lead sponsor
Imam Abdulrahman Bin Faisal UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 23, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Sickle cell disease (SCD) is a prevalent inherited blood disorder characterized by vaso-occlusive crises (VOCs), which lead to severe pain and complications. Despite hydration being a cornerstone of VOC management, the optimal fluid strategy remains uncertain. This study evaluates restrictive versus liberal fluid management strategies in patients with acute VOC. This multi-center, open-label, non-inferiority RCT will enroll patients with SCD presenting with acute VOC. Participants will be randomized to either a restrictive or liberal intravenous fluid management protocol. Primary outcome is pain score reduction. Secondary outcomes include time to pain resolution, ED length of stay, hospital admission rate, cumulative opioid dose, adverse events (incidence of fluid overload, pulmonary congestion), acute chest syndrome, incidence of acute kidney injury, revisit rates within 72 hours of ED discharge, need for intensive care or high-dependency unit admission, need for additional interventions, and 28 days overall mortality. Data will be analyzed using intention-to-treat principles. We hypothesize that a restrictive fluid strategy will achieve non-inferior pain control compared to a liberal strategy, while minimizing fluid-related complications. This study will provide evidence to inform clinical guidelines for fluid management in SCD patients experiencing VOCs.

Conditions

  • SCD
  • Vaso Occlussive Crisis

Interventions

  • Sodium Chloride (NaCl) 0.9 %Drug

    Keep vein open rate

  • Sodium Chloride (NaCl) 0.9 %Drug

    IV bolus of 20 mL/kg of normal saline over 1 hour, followed by maintenance fluids at 1.5-2 ml/kg times the calculated daily maintenance requirements

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Pain intensityTime frame: Baseline (within 30 minutes post admission), 1 hour, then hourly until ED discharge or 24- 48- and 72-hours post-admission ( for admitted patients)

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • John Hopkins Aramco Healthcare

    Dhahran, Saudi Arabia · Recruiting

  • King Fahad Military Medical Complex

    Dhahran, Saudi Arabia · Recruiting

  • Jubail General Hospital

    Jubail, Saudi Arabia · Recruiting

  • King Saud University Medical City

    Riyadh, Saudi Arabia · Recruiting

  • King Fahd Hospital of the University

    Dammam, Eastern Province, Saudi Arabia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.